MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Johnson and Johnson

Abrir

SetorSaúde

153.75 -0.54

Visão Geral

Variação de preço das ações

24h

Atual

Mín

152.41

Máximo

155.08

Indicadores-chave

By Trading Economics

Rendimento

3.4B

Vendas

20M

23B

P/E

Médio do Setor

17.455

57.333

EPS

2.77

Rendimento de Dividendos

3.3

Margem de lucro

15.235

Funcionários

138,100

EBITDA

652M

5.9B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.18% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.30%

2.63%

Próximos Ganhos

16 de jul. de 2025

Próxima data de dividendos

10 de jun. de 2025

Próxima data de ex-dividendo

27 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

11B

378B

Abertura anterior

154.29

Fecho anterior

153.75

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Johnson and Johnson Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de abr. de 2025, 15:12 UTC

Ganhos

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 de abr. de 2025, 10:35 UTC

Principais Notícias
Ganhos

J&J Increases Outlook After Beating 1Q Expectations

18 de abr. de 2025, 11:00 UTC

Principais Notícias

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 de abr. de 2025, 20:34 UTC

Ganhos

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 de abr. de 2025, 18:24 UTC

Ganhos

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 de abr. de 2025, 19:06 UTC

Ganhos

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 de abr. de 2025, 18:52 UTC

Conversa de Mercado
Ganhos

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 de abr. de 2025, 14:54 UTC

Ganhos

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 de abr. de 2025, 13:19 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 de abr. de 2025, 11:52 UTC

Ganhos

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 de abr. de 2025, 11:14 UTC

Ganhos

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 de abr. de 2025, 10:51 UTC

Ganhos

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 de abr. de 2025, 10:37 UTC

Principais Notícias
Ganhos

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

15 de abr. de 2025, 10:20 UTC

Ganhos

Johnson & Johnson 1Q EPS $4.54 >JNJ

Comparação entre Pares

Variação de preço

Johnson and Johnson Previsão

Preço-alvo

By TipRanks

9.18% parte superior

Previsão para 12 meses

Média 169.15 USD  9.18%

Máximo 185 USD

Mínimo 159 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Johnson and Johnson - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

7

Comprar

7

Manter

0

Vender

Pontuação Técnica

By Trading Central

154.36 / 157.47Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.